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a b s t r a c t
1-(3-Aminopropyl)imidazole (Apim) reacts with salicylaldeh yde and a selection of imidazole aldehydes 
and the resulting Schiff base ligands readily coordinate to Zn(II), Cu(II) and Ag(I) centres. X-ray crystal 
structures were obtained for two of the free ligands and also the Ag(I) complex of the Apim-salicylalde- 
hyde ligand. Encouragingly, all of free ligands and most of their metal complexes are relatively non-toxic, 
in vivo , towards Galleria mellonella . Although the free ligands and the Cu(II) and Zn(II) complexes are inac- 
tive, in vitro , against a selection of microbial pathogens, most of the Ag(I) complexes exhibit moderate 
anti-bacterial activity and good anti-fungal activity. 
 2013 Elsevier Ltd. All rights reserved. 
1. Introduction 
In recent years, metal complexes comprising Schiff base 
ligands have been shown to exhibit significant anticancer, 
antiviral and antimicrobial activity [1–4]. Commercially available 
1-(3-aminopropyl)imidazole (Apim) (Fig. 1) has recently been 
complexed to the Ag(I) ion and the structurally characterised 
complexes, [Ag(Apim)]ClO4 [5] and [Ag(Apim)](9-aca)H2O
(9-acaH = 9-anthracen ecarboxylic acid) [6], exhibit high antimi- 
cro bia l act ivi ties , in vit ro . In add iti on , me tal com ple xes com pri sin g
Schiff base ligands derived from Apim have also attracted atten- 
tion. For example, polymeric Ag(I) complexes of 3 (Fig. 1) show 
interesting structural and luminescen t propertie s [7], whilst 
Co(II), Ni(II), Cu(II), Zn(II) and Cd(II) complexes of 2 have been 
screened for their ability to inhibit the growth of bacterial and 
fungal pathogen s [8].
In the present paper we detail the synthesis, coordinatio n
chemistry, in vivo toxicity and antimicrobial activities of the unco- 
ordinated Apim-derive d Schiff base ligands 2–6 (Fig. 1) and their 
Ag(I), Cu(II) and Zn(II) complexes. 
2. Experimen tal 
2.1. Reagents and instrumentation 
1H and 13C NMR (d ppm; J Hz) spectra were recorded on a
BrukerAvan ce 300 MHz NMR spectromete r using saturated 
d6-DMSO solutions with Me4Si reference, unless indicated otherwise,
with resolutions of 0.18 Hz and 0.01 ppm, respectively . Infrared 
spectra (cm1) were recorded as KBr discs using a Perkin Elmer 
System2000 FT-IR spectromete r. UV–vis spectra were run on a
Unicam UV 540 spectromete r. Melting point analyses were car- 
ried out using a Stewart Scientific SMP 1 melting point apparatus 
and are uncorrected. Electrospray (ESI) mass spectra were col- 
lected on an Agilent Technologie s 6410 Time of Flight LC/MS. 
Compounds were dissolved in acetonitrile–water (1:1) solutions 
containing 0.1% formic acid, unless stated otherwise. The inter- 
pretation of mass spectra was made with the help of the pro- 
gram, ‘‘Agilent Masshunter Workstation Software ’’. Magnetic 
susceptibi lity measurements were carried out at room tempera- 
ture using a Johnson Matthey Magnetic Susceptibility Balance 
with [HgCo(SCN)4] as reference. Microanal ytical data were car- 
ried out using an Electron Corporation Thermo FlashEA 1112 Ser- 
ies analyser. Starting materials were commerciall y obtained and 
used without further purification.
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Caution! Although not encountered in our experiments , per- 
chlorate salts of metal ions are potential ly explosive and should 
be manipulate d with care and used only in small quantities. 
2.2. Synthesis of ligands 
2.2.1. 2-([3-(1H-imidazol-1- 
yl)propyl]aminopropylimino methyl)phenol (2)
This compound was prepared using a method similar to those 
previously reported [8,9]. To a solution of Apim (5.43 g, 43.4 mmol)
in dry methano l (30 mL) was added salicylaldehyd e (5.30 g, 
43.4 mmol) with constant stirring. The resulting yellow solution 
was refluxed for 3 h and then stirred overnight at room tempera- 
ture. The solvent was then removed under reduced pressure to give 
a yellow oil, which, on standing for 4 h, yielded yellow crystals of 2.
The crystals were recrystallise d from toluene, filtered, washed with 
cold, dry methanol and air-dried (9.5 g, yield 95%). M.p. 83–84 C
(lit. 78–80 C). C13H15N3O (229.28): Calc. C, 68.10; H, 6.59; N, 
18.33. Found: C, 68.23; H, 6.40; N, 18.24%. 1H NMR (d6-DMSO):
d = 13.36 (br s, 1H), 8.54 (s, 1H), 7.64 (s, 1H), 7.43 (d, 1H, 
J = 6.3 Hz), 7.34 (t, 1H, J = 6.6 Hz), 7.21 (s, 1H), 6.91 (m, 3H), 4.05 
(t, 2H, J = 6.9 Hz), 3.54 (t, 2H, J = 6.9 Hz), 2.10 (p, 2H, J = 6.9, 
7.2 Hz) ppm. 13C NMR (d6-DMSO): d = 166.3, 160.5, 137.2, 132.3, 
131.6, 128.5, 119.2, 118.6, 118.5, 116.4, 55.4, 43.8, 31.6 ppm. IR 
(KBr): m = 3434, 3101, 1632, 1576, 1491, 1401, 1276, 1225, 1151, 
1079, 887, 808, 760 cm 1. LC/TCOF-MS: Calc. for C13H16N3O
[M+1]+ 230.3. Found: 230.1%. 
2.2.2. N-[(E)-1H-Imidazol-5-ylmethy lidene]-N-[3-(1H-imidazol- 1- 
yl)propyl]amine (3)
This compound was prepared using a method similar to those 
previously reported [7]. To a solution of Apim (2.83 g, 22.6 mmol)
in dry methanol (17 mL) was added 4(5)-imidazolecarboxaldeh yde 
(2.17 g, 22.6 mmol). The resulting light-yellow suspension was 
heated to reflux for 3 h and the yellow solution was then stirred 
overnight at room temperature . The solvent was removed under 
reduced pressure to give an orange-yellow oil, which, on standing 
for 2 h, yielded the orange-y ellow solid (3). The solid was recrystal- 
lised from hot ethanol, filtered, washed with cold, dry ethanol and 
air-dried (4.3 g, yield 94%). M.p. 178–180 C (lit. 180–182 C).
C10H13N5(203.24): Calc. C, 59.09; H, 6.45; N, 34.46. Found: C, 
59.14; H, 6.28; N, 34.46%. 1H NMR (d6-DMSO): d = 12.59 (br s, 
1H), 8.19 (s, 1H), 7.74 (s, 1H), 7.63 (s, 1H), 7.19 (s, 1H), 6.90 (s,
1H), 4.03 (t, 2H, J = 6.9 Hz), 3.42 (t, 2H, J = 6.6 Hz), 2.01 (p, 2H, 
J = 6.9, 6.6 Hz) ppm. 13C NMR (d6-DMSO): d = 137.2, 128.4, 119.2, 
57.2, 43.9, 31.9 ppm. IR (KBr): m = 3436, 3137, 3103, 2844, 1647, 
1509, 1429, 1355, 1307, 1236, 1220, 1111, 1081, 1026, 827, 
749 cm 1. LC/TCOF-MS: Calc. for C10H14N5 [M+1]+ 204.2. Found: 
204.1%.
2.2.3. N-[(E)-1H-Imidazol-2-ylmethyli dene]-N-[3-(1H-imidazol-1- 
yl)propyl]amine (4)
To a solution of Apim (2.81 g, 22.5 mmol) in dry methanol 
(17 mL) was added imidazole-2-ca rboxaldehyde (2.17 g, 
22.5 mmol). The resulting solution was heated to reflux for 3 h
and then stirred overnight at room temperat ure. The solvent was 
removed under reduced pressure to give a brown oil, which, on 
standing for 2 months, yielded the orange-brown solid (4)
(3.69 g, yield 86%). M.p. 44–46 C. C10H13N50.5H2O (212.15): Calc. 
C, 56.56; H, 6.59; N, 33.01. Found: C, 56.08; H, 6.32; N, 32.87%. 1H
NMR (d6-DMSO): d = 8.17 (s, 1H), 7.65 (s, 1H), 7.19 (s, 1H), 7.13 (s,
1H), 7.11 (s, 1H), 6.91 (s, 1H), 4.06 (t, 2H, J = 6.9 Hz), 3.43 (t, 2H, 
J = 6.0 Hz), 2.01 (t, 2H, J = 6.9 Hz) ppm. 13C NMR (d6-DMSO):
d = 152.3, 144.4, 137.2, 128.2, 119.4, 56.7, 43.9, 31.7 ppm. IR 
(KBr): m = 3114, 1650, 1513, 1446, 1397, 1232, 1109, 1083, 
771 cm 1. LC/TCOF-MS: Calc. for C10H14N5 [M+1]+ 204.2. Found: 
204.1%.
2.2.4. 3-(1H-Imidazol-1-yl)-N-[(E)-(5-methyl-1H-imidazol-4- 
yl)methylidene]-1-propa namine (5)
To a solution of Apim (2.81 g, 22.5 mmol) in dry methanol 
(17 mL) was added 4-methyl-5- imidazolecarbox aldehyde (2.17 g, 
22.5 mmol). The resulting light-yellow suspension was heated to 
reflux for 3 h. The suspensi on was dissolved complete ly after 
5 min. The solution was then stirred overnight at room tempera- 
ture. After 0.5 h the solution turned orange in colour. The solvent 
was removed under reduced pressure to give an orange oil, which, 
on standing for 3 weeks, yielded the orange solid (5) (3.10 g, yield 
76%). M.p. 113–115 C. C11H15N5 (217.27): Calc. C, 60.81; H, 6.96; 
N, 32.23. Found: C, 60.60; H, 6.72; N, 31.35%. 1H NMR (d6-DMSO):
d = 8.23 (s, 1H), 7.64 (s, 1H), 7.61 (s, 1H), 7.18 (s, 1H), 6.91 (s, 1H),
4.04 (t, 2H, J = 7.2 Hz), 3.42 (t, 2H, J = 6.6 Hz), 2.32 (s, 3H), 2.03 (p,
2H, J = 6.9, 6.6 Hz) ppm. 13C NMR (d6-DMSO): d = 137.2, 128.3, 
119.3, 57.3, 48.5, 43.9, 32.1 ppm. IR (KBr): m = 3113, 1643, 1529, 
1452, 1395, 1354, 1233, 1110, 1082, 826, 747 cm 1. LC/TCOF-MS: 
Calc. for C10H14N5 [M+1]+ 218.3. Found 218.1%. 
2.2.5. 3-(1H-Imidazol-1-yl)-N-[(E)-(1-methyl-1H-imidazol-2- 
yl)methylidene]-1-propa namine (6)
To a solution of Apim (2.81 g, 22.5 mmol) in dry methanol 
(17 mL) was added 1-methyl-2- imidazolecarbox aldehyde (2.47 g, 
22.5 mmol). The resulting light-yellow solution was refluxed for 
3 h and then stirred overnight at room temperature. After 0.5 h
the solution turned orange in colour. The solvent was removed un- 
der reduced pressure to give the yellow oil (6) (3.11 g, yield 73%).
C11H15N5 (217.27): Calc. C, 60.81; H, 6.96; N, 32.23. Found: C, 
60.20; H, 6.35; N, 31.83%. 1H NMR (d6-DMSO): d = 8.25 (s, 1H),
7.64 (s, 1H), 7.30 (s, 1H), 7.20 (s, 1H), 7.04 (s, 1H), 6.90 (s, 1H),
4.07 (t, 2H, J = 7.5 Hz), 3.92 (s, 3H), 3.51 (t, 2H, J = 6.9 Hz), 2.05 
(p, 2H, J = 6.9, 6.9 Hz) ppm. 13C NMR (d6-DMSO): d = 153.6, 142.3, 
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Fig. 1. Structures of Apim (1) and its Schiff base derivatives, 2–6.
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137.2, 128.5, 128.3, 125.6, 119.3, 57.6, 43.9, 34.9, 31.8 ppm. IR 
(KBr): m = 3371, 3112, 1651, 1509, 1480, 1439, 1289, 1231, 1151, 
1082, 774 cm 1. LC/TCOF-MS: Calc. for C10H14N5 [M+1]+ 218.3.
Found: 218.2%. 
2.3. General synthesis of silver(I) complexe s
All of the Ag(I) complexes were synthesised with the exclusion 
of light and samples were stored in the dark. To a solution of the 
appropriate ligand (6.07 mmol) in dry methanol (47 mL) was 
added, dropwise , a solution of AgClO 4 (2.89 mmol) in dry methanol 
(5 mL) with constant stirring. The white suspensi on was then 
stirred for 2 h at room temperature. The solid was removed by 
filtration and washed with cold methanol to yield either white or 
pale-coloured solids, which were recrystallised from either hot 
acetonitrile or hot ethanol and air-dried .
2.3.1. [Ag(2)2]ClO4
Pale yellow solid recrystallise d from hot acetonitrile (1.48 g, 
yield 77%). C26H30AgClN6O6 (665.88): Calc. C, 46.90; H, 4.54; N, 
12.62. Found: C, 46.34; H, 4.37; N, 13.14%. 1H NMR (d6-DMSO):
d = 13.28 (br s, 2H), 8.55 (s, 2H), 8.07 (s, 2H), 7.50 (d, 2H, 
J = 1.2 Hz), 7.46 (s, 2H), 7.34 (m, 2H), 7.12 (m, 2H), 6.91 (m, 2H),
4.18 (t, 4H, J = 6.9 Hz), 3.58 (t, 4H, J = 6.6 Hz), 2.16 (t, 4H, 
J = 6.9 Hz) ppm. 13C NMR (d6-DMSO): d = 166.4, 160.4, 139.1, 
132.3, 131.6, 129.1, 120.2, 118.6, 118.5, 116.4, 55.4, 44.8, 
31.3 ppm. IR (KBr): m = 3432, 3138, 1633, 1579, 1499, 1393, 1278, 
1240, 1089, 837, 766 cm 1. LC/TCOF- MS: Calc. for C26H30AgN6O2
[Ag(2)2]+ 567.2, found 567.1; Calc. for C13H15AgN3O [Ag(2)]+
336.1. Found: 336.0%. Solubility: MeOH (hot), EtOH (hot), MeCN, 
CHCl3, DMSO. 
2.3.2. [Ag(3)]ClO4
White solid (0.66 g, yield 28%). C10H13AgClN5O4 (410.56): Calc. 
C, 29.25; H, 3.19; N, 17.06. Found: C, 29.29; H, 3.05; N, 17.23%. 
1H NMR (d6-DMSO): d = 13.16 (br s, 1H), 8.52 (s, 1H), 8.24 (s,
1H), 7.96 (s, 1H), 7.88 (s, 1H), 7.44 (s, 1H), 7.11 (s, 1H), 4.12 (t,
2H, J = 7.8 Hz), 3.67 (t, 2H, J = 5.7 Hz), 2.06 (t, 2H, J = 8.1 Hz) ppm. 
13C NMR (d6-DMSO): d = 155.2, 138.9, 138.6, 136.4, 129.2, 122.3, 
120.5, 55.5, 44.8, 32.4 ppm. IR (KBr): m = 3252, 3130, 2952, 
2854, 1648, 1519, 1447, 1298, 757 cm 1. LC/TCOF- MS: Calc. for 
C10H13AgN5 [Ag(3)]+ 310.1, found 310.0; Calc. for C20H26AgN10
[Ag(3)2]+ 513.3. Found: 513.1%. Solubility : DMSO. 
2.3.3. [Ag(4)]ClO4
Pale-orange solid (0.56 g, yield 22%). C10H13AgClN5O4 (410.56):
Calc. C, 29.25; H, 3.19; N, 17.06. Found: C, 29.56; H, 3.54; N, 16.41%. 
1H NMR (d6-DMSO): d = 8.39 (s, 1H), 7.94 (s, 1H), 7.50 (s, 1H), 7.47 
(s, 1H), 7.42 (s, 1H), 7.17 (s, 1H), 4.12 (t, 2H, J = 7.2 Hz), 3.70 (t, 2H, 
J = 6.6 Hz), 2.06 (t, 2H, J = 7.4 Hz) ppm. 13C NMR (d6-DMSO):
d = 181.1, 152.3, 145.5, 144.4, 137.3, 129.1, 128.2, 119.4, 56.7, 
43.9, 31.7 ppm. IR (KBr): m = 3313, 3129, 2939, 1645, 1520, 1448, 
1240, 1108, 834, 766 cm 1. LC/TCOF-MS: Calc. for C10H13AgN5
[Ag(4)]+ 310.2, found 310.0; Calc. for C20H26AgN10 [Ag(4)2]+
513.3. Found: 513.1%. Solubility: DMSO. 
2.3.4. [Ag(5)]ClO4
White solid (1.26 g, yield 52%). C11H15AgClN5O4 (424.59): Calc. 
C, 31.12; H, 3.56; N, 16.49. Found: C, 30.50; H, 3.30; N, 16.52%. 
1H NMR (d6-DMSO): d = 12.99 (br s, 1H), 8.58 (s, 1H), 8.09 (s, 1H),
7.96 (s, 1H), 7.43 (s, 1H), 7.11 (s, 1H), 4.11 (t, 2H, J = 8.4 Hz), 3.67 
(t, 2H, J = 6.6 Hz), 2.39 (s, 3H), 2.07 (p, 2H, J = 6.9, 7.4 Hz) ppm. 
13C NMR (d6-DMSO): d = 154.6, 138.6, 137.8, 132.2, 129.2, 120.5, 
55.5, 44.8, 32.5, 8.6 ppm. IR (KBr): m = 3259, 2928, 1643, 1519, 
1453, 1343, 1240, 1107, 996, 840, 804, 738 cm 1. LC/TCOF- MS: 
Calc. for C11H15AgN5[Ag(5)]+ 324.1. Found: 324.0%. Solubility: 
DMSO.
2.3.5. [Ag(6)]ClO4
White solid (1.84 g, yield 75%). C11H15AgClN5O4 (424.59): Calc. 
C, 31.12; H, 3.56; N, 16.49. Found: C, 31.42; H, 3.45; N, 16.03%. 
1H NMR (d6-DMSO): d = 8.67 (s, 1H), 7.95 (s, 1H), 7.64 (s, 1H),
7.43 (s, 1H), 7.32 (s, 1H), 7.11 (s, 1H), 4.12 (t, 2H, J = 7.5 Hz), 3.95 
(s, 3H), 3.75 (t, 2H, J = 5.7 Hz), 2.08 (t, 2H, J = 7.2 Hz) ppm. 13C
NMR (d6-DMSO): d = 150.2, 142.8, 138.7, 129.3, 129.2, 126.1, 
120.5, 55.9, 44.8, 32.5, 31.9 ppm. IR (KBr): m = 3448, 3123, 2940, 
1635, 1516, 1492, 1449, 1426, 1327, 1292, 1248, 1074, 948, 818, 
780, 701 cm 1. LC/TCOF- MS: Calc. for C11H15AgN5 [Ag(6)]+ 324.1.
Found: 324.0%. Solubility: DMSO. 
2.4. General synthesis of copper(II) complexes 
To a solution of the appropriate ligand (2.18 mmol) in 
dry methano l (17 mL) was added, dropwise, a solution of 
Cu(ClO4)26H2O (0.55 mmol) in dry methanol (2 mL) with constant 
stirring. The green suspension was then stirred for 3 h at room 
temperat ure. The resulting solid was removed by filtration and 
washed with cold ethanol and air-dried to yield either a green or 
a blue solid. 
2.4.1. [Cu(2)4](ClO4)2
Dark green solid (0.22 g, yield 48%). C52H60Cl2CuN12O12
(1179.56): Calc. C, 52.95; H, 5.13; N, 14.25. Found: C, 53.19; H, 
4.90; N, 13.69%. IR (KBr): m = 3446, 3130, 1622, 1539, 1450, 1404, 
1329, 1278, 1237, 1203, 1092, 833, 759 cm 1. LC/TCOF-MS: Calc. 
for C26H29CuN6O2 [Cu(2)2]+ 521.1. Found: 521.2%. leff: 2.53 B.M. 
Solubility : MeCN (hot), DMSO. 
2.4.2. [Cu(3)2](ClO4)2H2O
Green solid (0.42 g, yield 50%). C20H28Cl2CuN10O9 (686.95): Calc. 
C, 34.97; H, 4.10; N, 20.39. Found: C, 34.51; H, 3.93; N, 19.79%. IR 
(KBr): m = 3132, 2945, 1643, 1521, 1456, 1346, 1297, 1239, 1092, 
830, 752 cm 1. LC/TCOF-MS: Calc. for C20H26CuN10 [Cu(3)2]+
469.2. Found: 469.2%. leff: 1.93 B.M. Solubility: DMSO. 
2.4.3. [Cu(4)2](ClO4)2
Light-gre en solid (0.42 g, yield 51%). C20H26Cl2CuN10O8
(668.94): Calc. C, 35.91; H, 3.91; N, 20.94. Found: C, 36.13; H, 
3.88; N, 20.60%. IR (KBr): m = 3384, 3123, 2939, 1621, 1524, 
1455, 1237, 1089, 1027, 951, 762 cm 1. LC/TCOF- MS: Calc. for 
C20H27Cl2CuN10O8 [Cu(4)2](ClO4)2+H]+ 669.8. Found: 669.1%. leff:
1.97 B.M. Solubility: DMSO. 
2.4.4. [Cu(5)2](ClO4)2
Blue solid (0.48 g, yield 60%). C22H30Cl2CuN10O8 (696.99): Calc. 
C, 37.91; H, 4.34; N, 20.10. Found: C, 38.09; H, 4.33; N, 19.67%. IR 
(KBr): m = 3267, 3139, 2946, 1635, 1579, 1518, 1451, 1352, 1314, 
1280, 1239, 1099, 956, 827, 735 cm 1. LC/TCOF- MS: Calc. for 
C11H15CuN5 [Cu(5)]+ 280.8, found 280.1; Calc. for C22H30CuN10
[Cu(5)2]+ 497.2. Found: 497.2%. leff: 1.90 B.M. Solubility: DMSO. 
2.4.5. [Cu(6)2](ClO4)2H2O
Light-blu e solid (0.52 g, yield 65%). C22H32Cl2CuN10O9 (715.0):
Calc. C, 36.95; H, 4.51; N, 19.58. Found: C, 36.35; H, 4.31; N, 
18.85%. IR (KBr): m = 3436, 3144, 2950, 1633, 1523, 1485, 1452, 
1418, 1359, 1289, 1239, 1095, 950, 827, 769 cm 1. LC/TCOF-MS: 
Calc. for C22H30CuN10 [Cu(6)2]+ 497.2. Found: 497.2%. leff: 1.91 
B.M. Solubility : DMSO. 
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2.5. General synthesis of zinc(II) complexes 
To a solution of the appropriate ligand (2.18 mmol) in 
dry methanol (17 mL) was added, dropwise, a solution of 
Zn(ClO4)26H2O (0.55 mmol) in dry methanol (5 mL) with constant 
stirring. The suspension was then stirred for 2 h at room tempera- 
ture. The resulting solid was removed by filtration and washed 
with cold ethanol and air-dried to yield either stiff oils or solids. 
2.5.1. [Zn(2)(2)]ClO4
Stiff, yellow oil (0.22 g, yield 65%). C26H29ClN6O6Zn (622.38):
Calc. C, 50.17; H, 4.70; N, 13.50. Found: C, 50.27; H, 4.77; N, 
12.78%. 1H NMR (d6-DMSO): d = 13.29 (br s, 1H), 8.54 (s, 2H),
8.02 (s, 2H), 7.43 (d, 2H, J = 6.6 Hz), 7.34 (t, 2H, J = 7.8 Hz), 7.06 
(s, 2H), 6.89 (m, 4H), 4.14 (t, 4H, J = 7.2 Hz), 3.57 (t, 4H, 
J = 6.6 Hz), 2.14 (t, 4H, J = 6.9 Hz) ppm. IR (KBr): m = 3430, 3102, 
2935, 1633, 1578, 1492, 1459, 1401, 1277, 1225, 1151, 1080, 
809, 760 cm 1. LC/TCOF-MS: Calc. for C26H29ZnN6O2 [Zn(2)(2)]+
521.3. Found: 521.2%. Solubility: MeCN, DMSO. 
2.5.2. [Zn(3)2](ClO4)2
White solid (0.54 g, yield 66%). C20H26Cl2N10O8Zn (670.77):
Calc. C, 35.81; H, 3.91; N, 20.88. Found: C, 36.20; H, 3.86; N, 
20.16%. 1H NMR (d6-DMSO): d = 8.47 (s, 2H), 7.91(s, 2H), 7.63 (s,
2H), 7.14 (s, 2H), 6.86 (s, 2H), 3.88 (t, 4H, J = 7.5 Hz), 3.30 (t, 2H, 
J = 6.6 Hz), 1.70 (t, 2H, J = 6.8 Hz) ppm. IR (KBr): m = 3332, 3144, 
2954, 2867, 1645, 1527, 1452, 1299, 1236, 1111, 847, 759 cm 1.
LC/TCOF-MS: Calc. for C10H14N5 [ligand+1]+ 204.2. Found: 204.1%. 
Solubility: DMSO. 
2.5.3. [Zn(4)2](ClO4)2H2O
Light-orange solid (0.31 g, yield 60%). C20H28Cl2N10O9Zn
(688.81): Calc. C, 34.87; H, 4.10; N, 20.33. Found: C, 35.16; H, 
3.71; N, 19.63%. 1H NMR (d6-DMSO): d = 8.23 (s, 2H), 7.89 (s, 2H),
7.33 (s, 2H), 7.29 (s, 2H), 7.00 (s, 2H), 4.01 (t, 4H, J = 7.2 Hz), 3.40 
(t, 2H, J = 6.8 Hz), 1.83 (t, 2H, J = 7.0 Hz) ppm. IR (KBr): m = 3134, 
2940, 1644, 1527, 1455, 1241, 1101, 954, 767 cm 1. LC/TCOF-MS: 
Calc. for C20H27Cl2ZnN10O8 [Zn(4)2](ClO4)2+1]+ 671.1. Found: 
671.1%. Solubility: DMSO. 
2.5.4. [Zn(5)2](ClO4)2MeOH
White solid (0.53 g, yield 66%). C22H30Cl2N10O8ZnMeOH
(730.87): Calc. C, 37.80; H, 4.69; N, 19.16. Found: C, 37.86; H, 
4.26; N, 19.19%. 1H NMR (d6-DMSO): d = 13.18 (br s, 1H), 8.53 (s,
2H), 7.83 (s, 2H), 7.59 (s, 2H), 7.10 (s, 2H), 6.86 (s, 2H), 3.84 (t,
4H, J = 6.0 Hz), 3.29 (t, 4H, J = 5.7 Hz), 2.40 (s, 6H), 1.68 (t, 2H, 
J = 7.0 Hz) ppm. IR (KBr): m = 3246, 3135, 1644, 1597, 1528, 1456, 
1362, 1301, 1241, 1103, 967, 839, 749 cm 1. LC/TCOF-MS: Calc. 
for C11H16N5 [ligand+1]+ 218.3. Found: 218.1%. Solubility: DMSO. 
2.5.5. [Zn(6)2](ClO4)2H2O
White solid (0.53 g, yield 65%). C22H30Cl2N10O8ZnH2O (716.84):
Calc. C, 36.86; H, 4.50; N, 19.54. Found: C, 37.59; H, 4.25; N, 19.02%. 
1H NMR (d6-DMSO): d = 8.54 (s, 2H), 7.75 (s, 2H), 7.60 (s, 2H), 7.26 
(s, 2H), 7.05 (s, 2H), 6.91 (s, 2H), 4.10 (t, 4H, J = 7.2 Hz), 3.96 (s, 6H),
3.34 (t, 2H, J = 6.6 Hz), 1.78 (t, 2H, J = 7.2 Hz) ppm. IR (KBr):
m = 3607, 3135, 2958, 1639, 1531, 1496, 1451, 1418, 1381, 1291, 
1241, 1094, 944, 847 cm 1. LC/TCOF- MS: Calc. for C22H30ZnN10
[Zn(6)2]+ 498.3. Found: 497.2%. Solubility: DMSO. 
2.6. X-ray crystallography 
Data for 2, 3 and [Ag(2)2]ClO4 were collected at 150 K on a Bru- 
ker APEX II CCD diffractometer . The structures of 2 and [Ag(2)2]-
ClO4 were solved by direct methods and refined by full-matrix 
least-squares on F2 using all data [10]. All non-hydrog en atoms 
were refined with anisotropic atomic displacemen t parameters 
and the hydrogen atoms bonded to carbon were inserted at calcu- 
lated positions using a riding model. The hydrogen atom bonded to 
O1 in compound 2 was located from differenc e maps and refined
with a fixed isotropic thermal parameter. The structure of [Ag(2)2]-
ClO4 was solved by direct methods and found to be twinned. The 
twin components were identified (CELL_NOW and TWINABS) and 
the structure refined on F2 using all the reflections (HKLF 5 data)
[10]. All non-hydrog en atoms were refined with anisotropic atomic 
displacemen t parameters and the hydrogen atoms were inserted at 
calculated positions using a riding model. Data collection and 
refinement parameters for all three structures are summarized in 
Table 1.
2.7. Biology 
Sterilisat ion of microbiol ogical equipment and media was car- 
ried out at 394 K and 100 kPa for 15 min. All worktops and benches 
were sterilised by washing with 70% (v/v) ethanol–water prior to 
use. Flat-bottom ed microtitre plates were read using a Bio-Tek 
Synergy HT plate reader at 540 nm. Fungal cell density was mea- 
sured using a Neubauer hemocytomete r under a light microscope 
at a magnification of 400 . Bacterial cell density was recorded at 
an optical density of 600 nm using an Eppendo rf Biophotometer .
Galleria mellonella (larvae of the greater wax moth), in the sixth 
developmen tal stage, were obtained from Livefoods Direct Ltd., 
Sheffield, S25 4JJ, UK. The larvae were stored at 288 K in wood 
shavings and used within 3 weeks of delivery. Significance of the 
larvae survival rates was analysed at 72 h using the log rank (Man-
tel–Cox) method utilising GraphPad Prismsoftwar e (version 5).
Three categories of significance were used ( = p < 0.05, 
 = p < 0.01 and  = p < 0.001). Pseudomonas aeruginosa ATCC
27853, Methicillin- resistant Staphylococc us aureus (MRSA) and Can-
dida albicans ATCC 10231 were obtained from the American Type 
Culture Collectio n (Manassas, VA, USA). S. aureus and Escherichi a
coli were supplied as clinical isolates by the Clinical Microbiolog y
Laborato ry, St. James’s Hospital, Dublin, Ireland. 
2.7.1. In vivo toxicity assessmen t
Larvae of the insect G. mellonella were employed to assess the 
in vivo cytotoxic tolerance of the test compounds and AgNO 3. Such 
Table 1
Crystallographic data for 2, 3 and [Ag (2)2]ClO4.
2 3 [Ag(2)2]ClO4
Formula C13H15N3O C10H13N5 C26H30AgClN6O6
M (g mol 1) 229.28 203.25 665.88 
Crystal system monoclinic monoclinic triclinic 
Space group P21/c P21/n P1
T (K) 150(2) 150(2) 150(2)
a (Å) 12.3194(11) 8.6001(10) 5.915(7)
b (Å) 5.8438(5) 10.1425(12) 14.369(17)
c (Å) 16.3752(15) 12.3976(14) 16.897(19)
a () 90 90 79.644(16)
b () 97.963(2) 103.131(2) 83.636(16)
c () 90 90 88.369(17)
V (Å3) 1167.52(18) 1053.1(2) 1404(3)
Z 4 4 2
Dcalc (g cm 3) 1.303 1.282 1.575 
Reflections collected 9584 7985 5143 
Unique reflections 2753 2077 5143 
Rint 0.0260 0.0267 0.0000 
Obs. reflections [I > 2r(I)] 2004 1593 2701 
No. of parameters 157 136 365 
No. of restraints 0 0 353 
R1 [I > 2r(I)] 0.0389 0.0359 0.0723 
wR2 (all data) 0.1128 0.0885 0.1804 
Goodness-of-fit (GOF) 1.006 1.091 0.972 
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larvae have been widely used as a convenie nt and inexpensive 
in vivo screening model to assess the toxicity of potential new 
drugs [11,12]. Ten healthy larvae, weighing between 0.2–0.4 g
and with no cuticle discolourati on, were used for each compound. 
Fresh suspensions or solutions of the free ligands and their Ag(I),
Zn(II) and Cu(II) complexes were prepared immediately prior to 
testing under sterile conditions. Each sample (0.02 g) was sus- 
pended or dissolved in DMSO (1 mL) and sterile water (9 mL)
was added to yield a stock solution of concentr ation 2000 lg/mL.
Each sample was tested across the concentration range 2000–
100 lg/mL. Using serial dilutions with water, each sample was 
tested across the concentratio n range 2000–100 lg/mL and the fi-
nal concentration of DMSO was ca.1% v/v. Test solution (20 lL) was 
injected into the larvae through the last pro-leg and the larvae 
were then placed in sterile petri dishes and incubated for 72 h at 
30 C. Death was assessed by the lack of movement in response 
to stimulus, together with discolourati on of the cuticle. Three dif- 
ferent controls were used in this assay: the first was untouched lar- 
vae; the second was larvae with the pro-leg pierced with a needle 
but no solution injected; the third was larvae injected with sterile 
distilled water (20 lL).
2.7.2. In vitro antimicrobial assessment 
In vitro antimicrobial screening: Minimal growth media (MM)
was prepared as previously described [13]. Yeast extract peptone 
dextrose (YEPD) media was composed of 2% (w/v) glucose, 2% 
(w/v) bacteriol ogical peptone and 1% (w/v) yeast extract. To solid- 
ify the media 2% (w/v) bacteriological agar was added when re- 
quired. Nutrient broth and phosphate buffered saline (PBS) were 
made up accordin g to the manufactur er’s instructions (Scharlau
Microbiolog y and Aldrich, respectively ).
In vitro bacterial susceptibi lity testing: Bacteria were grown on 
nutrient broth agar plates at 310 K and maintained at 277 K for 
short-term storage. All assays were run in triplicate and on three 
independen t occasions . Complexes with low solubility were tested 
as fine suspensions . Fresh solutions/s uspensions of the test sam- 
ples were prepared immediatel y prior to testing. Samples 
(0.020 g) were added to DMSO (1 mL) and then water (9 mL) was 
added to give a stock solution/suspens ion (concentration 
2000 lg/mL). The stock solution (1 mL) was added to water 
(9 mL) to yield a solution/ suspension with a concentratio n of 
200 lg/mL. Nutrient broth (100 lL) was added to each well of a
96-well, flat-bottomed microtitre plate. Water (100 lL) was added 
to column 1 of the plate (negative control with no bacterial cells).
Column 2 was the positive control (media with bacterial cells).
100 lL of the above complex solution (200 lg/mL) was added to 
every well in column 3. Serial dilutions (1:1) were made from col- 
umn 3–12 to produce a test concentration range of 100–0.2 lg/mL.
Bacteria were grown overnight to the stationary phase in nutrient 
broth at 310 K and 200 rpm. The cells were diluted to give an opti- 
cal density of 0.1 at k = 600 nm. The cell suspension (100 lL) was 
added to every well in columns 2–12. The completed plates were 
incubated at 310 K in a static incubator and the final optical den- 
sity recorded. MIC 50 values (minimum concentr ation required to 
inhibit 50% of cell growth) were then determined and expressed 
in terms of lM concentratio n. 
In vitro fungal susceptibility testing: C. albicans was grown on 
YEPD agar plates at 310 K and maintained at 277 K for short-term 
storage. All assays were run in triplicate and on three independen t
occasions. Fresh solutions/susp ensions of test samples were pre- 
pared immediatel y prior to testing. Samples (0.020 g) were dis- 
solved/susp ended in DMSO (1 mL) and added to water (9 mL) to 
give a stock solution (concentration 2000 lg/mL). The stock solu- 
tion/suspen sion (1 mL) was added to water (9 mL) to give a solu- 
tion with a concentration of 200 lg/mL. MM (100 lL) was added 
to each well of a 96-well, round bottomed microtitre plate. Water 
(100 lL) was added to column 1 of the plate (negative control, 
media with no fungal cells). Column 2 was the positive control 
(media and fungal cells only). 100 lL of the above complex solu- 
tion (200 lg/mL) was added to every well in column 3. Serial dilu- 
tions (1:1) were made from columns 3–12 to produce a test 
concentr ation range of 100–0.2 lg/mL.
C. albicans was grown to the stationary phase overnight at 310 K
on YEPD media. The cells were washed with PBS solution and 
re-suspe nded in MM at a density of 5  105 cells/mL. The cell sus- 
pension (100 lL) was added to every well in columns 2–12. The 
complete d plate was then covered to prevent dehydrati on. The 
plate was incubated at 310 K with continuous shaking for 24 h. 
The optical density (k = 540 nm) of each well was then recorded. 
MIC80 value ranges were then determined and expressed in terms 
of lM concentratio n. 
3. Results and discussion 
3.1. Ligand synthesis 
The Schiff base ligands 2–6 (Fig. 1) were formed in high yield by 
the reaction of 1-(3-aminopropyl)imidazole (Apim) with salicylal- 
dehyde and the various imidazole aldehydes in dry methanol. Li- 
gand composition was determined by a combinati on of elemental 
analyses, mass spectrometry and 1H and 13C NMR and IR spectros- 
copy. The formation of the Schiff base products was confirmed by 
1H NMR spectroscopy (imine proton singlet at ca. 8.2 ppm) and IR 
spectroscopy (imine C@N band at ca.1650 cm 1).
3.2. X-ray structures of ligands 2 and 3
Although the synthesis of 2 has previously been documented 
[8,9] its X-ray crystal structure was not reported. Crystals of 2
and 3 were grown from saturated methanol solutions of both com- 
pounds. The asymmetric units for each compound are shown in 
Figs. 2 and 4 and selected bond lengths and angles are given in 
Table 2. In compound 2, there is an intramolecu lar hydrogen bond 
between the phenolic hydrogen atom and the imine nitrogen atom 
(N3).
The packing interactions of 2 are illustrated in Fig. 3. There is a
C–H  p bonding interaction between the centroid of each imidaz- 
ole ring and a hydrogen of the C4 methylene group of the spacer 
chain of a neighbouring molecule (centroid–H 2.59 Å). There is 
an interplanar angle of 88.76(4) between the imidazole and phe- 
nol rings but there are no striking p–p stacking interactions. 
In compound 3, the imine bond is clearly located between N3 
and C7. There is a hydrogen bond linking N4 to the imine nitrogen 
of a neighbouring molecule (2.991(2) Å under ½  x, ½ + y, ½  z),
and a weaker bond from the same NH to N5 of the same neighbour 
(3.079(2) Å). These interactions link the molecules into chains. 
There is also a weak C–H  N interaction between C10 and N1 
(the imidazol e lone pair) of a second neighbour (3.38(2) Å under 
Fig. 2. Asymmetric unit of 2 showing intramoleular hydrogen bonding. 
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x, y, z + 1) and including this interaction gives sheets of molecules 
in the plane perpendicular to the a axis (Figs. 5, 6 and Table 2).
3.3. Metal complex syntheses and characterisati on 
The Schiff base ligands (2–6) reacted with Ag(I), Cu(II) and Zn(II)
perchlorate salts at room temperature to give the respective metal 
complexes in high yield. The five Ag(I) complexes were reasonably 
soluble in DMSO. Four of the complexes formulated with a 1:1 
Ag:ligand ratio and the remaining complex, [Ag (2)2]ClO4, had a
1:2 ratio. In the case of the Cu(II) complexes, four formed with a
1:2 Cu:ligand ratio and the remaining complex, [Cu(2)4](ClO4)2,
had a 1:4 ratio. Repeated attempts to grow crystals of the latter 
complex proved unsuccessful. All of the Zn(II) complexes had a
1:2 Zn:ligand ratio, with [Zn(2)(2)](ClO4) being unusual in that 
this was the only complex in which one of the Schiff base ligands 
deprotonated (2) at the salicylate O-H moiety. Kalanithi et al. [8]
previously reported the synthesis of Cu(II), Zn(II), Co(II), Ni(II)
and Cd(II) complexes of 2, formed by reacting the appropriate me- 
tal chloride salt with 2 in a 1:1 M ratio. Their Cu(II) and Zn(II) com- 
plexes formulated as [Cu(2)Cl] and [Zn(2)Cl(H2O)2], showing 
that there was deprotonati on of the salicylate OH moiety of the 
single Schiff base ligand and coordination of the chloride ion. 
The IR spectra of all of the present complexes contained bands 
associate d with perchlorate anions (ca. 1100 and 625 cm 1). How- 
ever, it was difficult to see in many of the spectra of the metal com- 
plexes if there was a shift in the imine band (ca. 1650 cm 1) due to 
the complexity of the bands in the region. Several major differ- 
ences were observed between the 1H NMR spectra of the free li- 
gands in d6-DMSO and those of the Ag(I) and Zn(II) complexes of 
the same ligands. In all cases, the H–C@N proton signal corre- 
sponding to the imine of the chain was significantly shifted in 
the metal complexes, suggesting that binding of the metal ion at 
this N atom was occurring. Furthermore, there were also shifts in 
the signals associated with the imidazole ring systems, again indi- 
cating possible binding at the imidazole pyridine-type N atom. 
Interestin gly, there was no loss of the phenolic proton signal 
(13.28 ppm) in the spectrum of [Ag(2)2]ClO4, implying that depro- 
tonation of the phenol group did not occur. The signal for the imid- 
azole ring N–H proton in the spectra of the free ligands 3–5
becomes sharper and gets shifted upfield in the spectra of the 
Ag(I) or Zn(II) complexes containing these ligands. 
Crystals of [Ag(2)2]ClO4 suitable for X-ray crystallogra phic stud- 
ies were grown from a hot acetonitrile solution of the complex. The 
complex contains two independen t silver ions, each on a centre of 
symmetr y, so the asymmetric unit contains two half-molecules 
and one perchlorate anion (Fig. 7 and Table 2). The Ag(I) ion is 
bonded, with linear coordination, to the imidazole nitrogen donors 
and there is also intramolecu lar hydrogen bonding between the 
phenolic hydrogen atoms and the imine nitrogen atoms in the 
chains (N3A and N3B). Fig. 8 shows the resulting structure; alter- 
nating independen t [Ag(2)2]+ cations are linked into chains by 
the perchlorate anions which are weakly bonded to the metal ions. 
The anion acts as a bidentate ligand to Ag1 (O13–Ag1 and O14–Ag1
3.424(10) and 3.277(7) Å, respectively) and as a monodenta te li- 
gand to Ag2 (O12–Ag2, 2.895(8) Å). The N1A–Ag1–Ag2–N1B tor- 
sion angle is 113.6 . Between the chains there are weak 
hydrogen bonds between O1a and its equivalent under symmetr y
operation .
The X-ray structures of three Ag(I) complexes of 3 have previ- 
ously been reported [7]. [Ag 2(3)2](NO3)2 formed as an infinite 1D 
chain polymer where each of the two Ag(I) ions have different 
coordina tion environments , with one metal chelated by the imine 
N in the linker chain between the two imidazoles and the pyridine- 
type N on the imidazole ring closest to it, with the second metal 
bonded to the pyridine-type N on the imidazole ring at the further 
Fig. 3. Packing diagram for 2.
Fig. 4. Asymmetric unit of 3.
Table 2
Selected bond lengths [Å] and angles [] for 2, 3 and [Ag (2)2]ClO4.
2 3 [Ag(2)2]ClO4
C(1)–N(1) 1.3172(19) 1.317(2) 1.318(15)
C(1)–N(2) 1.3501(17) 1.350(2) 1.326(15)
N(1)–C(2) 1.372(2) 1.371(2) 1.368(14)
C(3)–N(2) 1.3683(16) 1.366(2) 1.347(14)
N(2)–C(4) 1.4609(17) 1.462(2) 1.473(14)
C(6)–N(3) 1.4613(17) 1.4617(19) 1.476(15)
N(3)–C(7) 1.2756(16) 1.272(2) 1.244(14)
C(9)–N(4) – 1.350(2) –
N(4)–C(10) – 1.350(2) –
C(10)–N(5) – 1.314(2) –
C(13)–O(1) 1.3531(16) – 1.349(15)
Ag(1)–N(1) – – 2.109(10)
N(1)–C(1)–N(2) 112.66(13) 112.39(15) 113.5(12)
C(1)–N(1)–C(2) 104.04(12) 104.33(14) 103.1(11)
C(1)–N(2)–C(3) 106.65(12) 106.41(14) 106.1(11)
C(1)–N(2)–C(4) 126.95(12) 127.34(14) 124.5(10)
C(3)–N(2)–C(4) 126.22(12) 126.23(14) 129.4(11)
C(7)–N(3)–C(6) 109.95(11) 118.10(13) 118.2(11)
C(10)–N(4)–C(9) – 107.01(12) –
N(5)–C(10)–N(4) – 112.59(14) –
C(10)–N(5)–C(8) – 104.38(13) –
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end of the ligand and the N from the same ring on an adjacent li- 
gand molecule. In the 2D polymeric network of [Ag 2(3)2](BF4)2
there are two crystallogra phically independent Ag(I) centres hav- 
ing the same coordination environment, with each metal coordi- 
nated by three N atoms from two different molecules of 3
(chelation by the imine N in the linker chain between the two imi- 
dazoles and the pyridine- type N on the closest imidazole ring, and 
by the pyridine-type N on the imidazole ring at the opposite end of 
an adjacent ligand molecule). [Ag 2(3)2](CH3CO2)2 features a dis- 
crete [Ag 2(3)2]2+ molecular ring with each metal triangularly coor- 
dinated by three N atoms from two different molecules of 3 (same
set of donor atoms as in [Ag 2(3)2](BF4)2). In the electrospray mass 
spectrum of [Ag 2(3)2](NO3)2 the authors report signals for [Ag(3)]+
(310.3), [Ag(3)2]+ (512.8), [Ag 2(3)2](NO3)2+(683.6). In the mass 
spectrum of the present complex, [Ag(3)]ClO4, we observe a large 
peak for the [Ag(3)]+ species and a much smaller peak for [Ag(3)2]+.
3.4. Biology 
3.4.1. Toxicity profiling
Larvae of the insect, G. mellonell a, were used to assess the in vivo 
toxicity of the test compounds (Table 3). At the maximum admin- 
istered dosage of the free ligands (ca. 0.2 lmol), none of the larvae 
died, except in the case of ligand 6, where 10% of the larvae ex- 
pired. These findings suggest that the ligands do not pose signifi-
cant toxicity issues to the insect. In addition, all of the Cu(II) and 
Zn(II) complexes displayed minimal toxicity. [Ag(2)2]ClO4 and
[Ag(3)]ClO4 were less well tolerated , and both of these complexes 
proved to be more destructive than AgNO 3, where significant
toxicity (30%) was only evident at the much higher dosage of 
0.235 lmol. It is interesting to note that, whereas [Ag(3)]ClO4
was quite toxic at the 0.197 lmol dosage level (90%
mortality ), the complex containing the isomeric ligand, 4 (i.e.
[Ag(4)]ClO4MeOH), did not cause any fatalities at this dose. 
3.4.2. Antimicrobial activity 
The free ligands and the Cu(II) and Zn(II) complexes were essen- 
tially inactive against all of the test microbes. The lack of activity 
found for uncoordinated ligand 2 and its Cu(II) and Zn(II) com- 
plexes is similar to that previously reported [8] for [Cu(2)Cl] and 
[Zn(2)Cl(H2O)2] against the same organisms (except MRSA, which 
was not tested). In contrast to the relative inactivity of 2, a related 
Schiff base, formed from Apim and 2-formylphenox yacetic acid, 
was found to be quite active in its uncoordinated form against 
Fig. 5. Partial packing diagram of 3 showing hydrogen bonds linking the molecules into chains. 
Fig. 6. Packing diagram of 3 showing sheets perpendicular to a. 
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strains of S. aureus and E. Coli (MIC100 value of 6.25 lg/ml in each 
case), indicating the importance of functionalization of the salicy- 
late phenyl ring [14]. In addition, the lack of antimicrobial potency 
of the present Cu(II) complexes differs markedly from that of 
[CuL(H2O)3]Cl2H2O (LH is a Schiff base ligand derived from L-his-
tidine and pyrrole-2-carbox aldehyde) [15], which proved to be 
Fig. 7. Asymmetric unit of [Ag(2)2]ClO4 containing two half-molecules and one anion. 
Fig. 8. Partial packing diagram of [Ag(2)2]ClO4 showing interactions between Ag(I) cations and perchlorate anions. 
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quite active against E. coli and C. albicans (MIC100 = 11.9 and 
19.0 lM, respectively ). The Zn(II) complex of the same ligand, 
[ZnL(H2O)]Cl, was essentiall y inactive. 
The anti-bacterial and anti-fungal activities of the new Ag(I)
complexes and the positive control, AgNO 3, are listed in Table 4.
[Ag(6)]ClO4 was the least active across all of the microbial species, 
and the activities of the other water-insolubl e Ag(I) complexes 
were similar to that observed for water-soluble AgNO 3. In these 
cases, activity against the fungal pathogen , C. albicans , was greater 
than that for bacterial pathogens, which is a trend similar to that 
previously reported for other Ag(I) complexes [5,6,16]. Although 
there was no clear discriminatory trends observed in activities be- 
tween Gram-positive (S. aureus and MRSA) and Gram-negati ve 
(E. coli and P. aeruginosa ) bacteria, most of the complexes, and 
especially [Ag(4)]ClO4MeOH, were more cytotoxic against 
P. aeruginosa . The growth inhibitory effects of the present Ag(I)
imidazole Schiff base complexes against MRSA and E. coli are sim- 
ilar to those recently documented for a series of Ag(I) complexes of 
9-anthracen ecarboxylic acid containing non-Schiff base imidazole 
ligands and also the clinically used compound, silver sulphadiazi ne 
[6]. However, some of the latter complexes displayed significantly 
greater anti- Candida activity compare d to the present complexes. 
In addition, the present Ag(I) complexes had activities similar 
to that of the prescription drug, miconazole (MIC90 against
C. albicans = 19 lM [17]).
Although there are close similarities in the antimicrobial activ- 
ities of the new Ag(I) complexes with that of the simple Ag(I) salt, 
AgNO3, it would appear that, from a therapeutic viewpoin t, some of 
complexes, and particular ly [Ag(4)]ClO4MeOH, are considerably 
less toxic than AgNO 3 towards the in vivo model, G. mellonell a.
4. Conclusion s
Schiff base ligands form readily and in high yield upon reacting 
Apim with salicylaldehy de and imidazole aldehydes. These Schiff 
bases readily coordinate to Ag(I), Cu(II) and Zn(II) centres. Encour- 
agingly, all of free ligands and most of their metal complexes are 
relatively non-toxi c, in vivo , towards G. mellonella . Whereas the 
uncoordi nated ligands and the Cu(II) and Zn(II) complexes are 
inactive against a selection of microbial pathogens, most of the 
Ag(I) complexes, as well as AgNO 3, exhibit moderate anti-bacterial 
activity and good anti-fungal activity. 
Appendi x A. Supplementar y data 
CCDC 916653–916655 contain the supplementary crystallo -
graphic data for 2, 3 and [Ag (2)2]ClO4, respectively . These data 
can be obtained free of charge via http://ww w.ccdc.cam.ac.uk /con- 
ts/retrievi ng.html , or from the Cambridge Crystallo graphic Centre, 
12 Union Road, Cambridge CB2 1EZ, UK: fax: (+44) 1223-336-033 ;
or e-mail: deposit@ccdc.c am.ac.uk. 
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